Skip to main content

Table 2 WT GIST patients

From: Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

PatientKIT mutationPDGFR mutationBRAF mutationSDHB expressionDuration on regorafenib (months)Best response to regorafenib as per RECIST 1.1Reason for discontinuing regorafenib
1NoNoNoNormal3.6PRToxicity
2NoNoUnknownUnknown18.3SDPD
3NoNoUnknownUnknown2.9SDPD
4NoNoNoNormal6.7SDPD